Drug Type Fusion protein |
Synonyms- |
Target |
Action antagonists |
Mechanism IL1R1 antagonists(Interleukin-1 receptor alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Digestive System Disorders | Discovery | - | 02 Jan 2024 | |
| Digestive System Disorders | Discovery | - | 02 Jan 2024 | |
| Immune System Diseases | Discovery | - | 02 Jan 2024 | |
| Immune System Diseases | Discovery | - | 02 Jan 2024 | |
| Rare Diseases | Discovery | - | 02 Jan 2024 | |
| Rare Diseases | Discovery | - | 02 Jan 2024 | |
| Respiratory Tract Infections | Discovery | - | 02 Jan 2024 | |
| Respiratory Tract Infections | Discovery | - | 02 Jan 2024 | |
| Skin and Musculoskeletal Diseases | Discovery | - | 02 Jan 2024 | |
| Skin and Musculoskeletal Diseases | Discovery | - | 02 Jan 2024 |






